Pharma and healthcare: sector news on Saturday 24 October 2026
Average tone +3.7 (positive) across 5 companies with relevant coverage, from 51 stories.
How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| Smith & Nephew | −5.7 | 21 | Coverage was almost entirely about reported talks on a Smith & Nephew tie-up with the orthopaedics arm of J&J, which ended over who would be CEO. |
| GSK | +8.0 | 15 | Coverage was mainly positive, led by FDA approvals including a hepatitis B treatment and new cancer drug licensing rights from HUTCHMED. |
| AstraZeneca | +9.2 | 8 | Coverage was mainly positive, with new approvals for Ultomiris in the US and Enhertu in China, plus a $1.46 billion AI deal. |
| Haleon | +2.3 | 5 | Coverage was mixed: a new Excedrin launch and an Advil marketing push were positive, while South African Sensodyne users reacted angrily to an ingredient change. |
| Convatec | +4.5 | 2 | Coverage centred on Convatec being highlighted for awards, innovation and growth prospects, which gives a modestly positive lean. |
Strongest stories in the sector
- +10.0 FDA approval of hepatitis B treatment is a major win.
- +10.0 Shares rise after approvals for Ultomiris and Zegfrovy.
- +10.0 FDA clears Ultomiris for a rare kidney condition in the US.
- +10.0 Enhertu wins conditional China approval for new indication.
- +10.0 Double FDA win highlighted.
- +10.0 FDA granted GSK two approvals within a single week.
- +9.2 Signs $1.46bn AI deal ahead of results.
- −8.7 Sensodyne customers in South Africa angry over ingredient change; reputational hit.
- +8.3 Analyst view calls shares undervalued ahead of Q3 results.
- +8.3 Approval win and Jefferies analyst backing.
- +7.5 Jefferies keeps high price target on shares.
- +7.5 Secures exclusive rights to first-in-class cancer therapy; pipeline boost.
Pharma and healthcare: every day · FTSE 100 overview for the day
Follow by email
A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.